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Abstract
Background: Desmoid tumors, which are associated with familial adenomatous polyposis (FAP), tend to occur
frequently in the abdominal wall and mesentery. Currently, there are no recognized treatments other than surgery,
and frequent surgeries result in gastrointestinal obstructions and functional gastrointestinal disorders.
Case presentation: After surgery that was performed on a 39-year-old patient with FAP, we performed a second
tumor excision which was the procedure used for frequently occurring mesenteric desmoid tumors. It was
determined that the enlarged tumor would be difficult to operate on through an abdominal incision. Subsequently,
the carbon ion radiotherapy of 50 Gy was then performed on the patient. Three years later, the tumor still remains
reduced in size. In addition, we have not observed any negative effect on the digestive tract.
Conclusions: This is the first instance that the carbon ion radiotherapy has been effective for the unresected
desmoid tumor, and it is believed that this will become the one effective option for the treatment of desmoid
tumors.
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Background
Desmoid tumors associated with familial adenomatous
polyposis (FAP) are classified as benign, but clinically
considered to be a disease similar to malignancies because
of their tendency to occur as multiple lesions in the ab-
dominal wall or mesentery. Surgical therapy is the first
choice of treatment, but repeated procedures for recurrent
tumors may cause gastrointestinal stenosis or dysfunction.
Although hormone therapy and chemotherapy for des-
moid tumors have been described in the literature, no
established treatment is available other than surgical re-
section. We report a case of inoperable growing desmoid
tumor in the abdominal wall that shrank in response to
heavy ion radiotherapy and has remained stable and free
of effects on the adjacent intestinal tract for 3 years. No
cases like this have been reported anywhere in the world.
We believe that heavy-ion radiotherapy has the potential
to become an effective treatment option for patients with
desmoid tumors.
Case presentation
The patient was a 49-year-old man diagnosed with
familial adenomatous polyposis (FAP) caused by a
defect in the adenomatous polyposis coli (APC) gene.
In March 1998 (aged 36), he underwent total proctoco-
lectomy and ileostomy for polyps involving the entire
colon, and the stoma was closed 9 months later. Patho-
logical findings showed that the polyps were adenomas.
In August 2001 (aged 39) and August 2003 (aged 41),
multiple mesenteric tumors were removed, which were
pathologically diagnosed as desmoid tumors character-
ized by invasive growth of fibroblasts into the sur-
rounding muscle layer. He subsequently experienced
repeated episodes of ileus symptoms attributable to in-
testinal adhesion as a postoperative complication and
to recurrent mesenteric desmoid tumors; thus, duodenoje-
junostomy was performed in March 2011 (aged 49).
Around December 2011, 9 months after the operation, a
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desmoid tumor of the abdominal wall was found immedi-
ately above the peritoneum just below the previous opera-
tive wound, which grew to 7.3 cm in the longest diameter
in 3 months (Fig. 1a). It was considered surgically unre-
sectable partly because tumor adhesion to the intestinal
tract and peritoneum was severe and partly because tumor
removal would have resulted in a large defect in the
abdominal wall. Among the available treatment options
for desmoid tumor of the abdominal wall, chemotherapy,
carbon ion radiotherapy, etc. were proposed. After a
thorough discussion about informed consent, the patient
selected carbon ion radiotherapy, which is a type of radio-
therapy that can deliver high-dose radiation to a tumor
while minimizing the dose delivered to the organs at risk.
From May to July 2012, he received carbon ion beam
irradiation at a total dose of 50 Gy (relative biological ef-
fectiveness [RBE])1 in 25 fractions at the Hyogo Ion Beam
Medical Center (HIBMC). Figure 1b shows the carbon ion
treatment plan for this patient. The solid abdominal wall
tumor continued to grow until 2 months after treatment,
reaching 12 cm in diameter, and then gradually shrank to
7.8 cm at 5 months. One year after treatment, the con-
tents of the tumor had liquefied, and the tumor had
shrunk to 4.3 cm in diameter. The liquid components
consisted primarily of fibrin, with no malignant cells.
Currently, 3 years after the operation, the abdominal wall
tumor remains stable, with a diameter of 3.3 cm, and is
being followed up (Fig. 1c).
Discussion
Desmoid tumor is a rare with 2.4~4.3 cases occurring
per one million individuals each year [1]. It has been
correlated with the FAP [2], and the overall incidence of
desmoid tumor in patients with FAP is 10–20 %, which
equates to relative risk of 852 compared to the general
population [3]. Desmoid tumor is a benign fibromatosis
that originate from fascia and muscular aponeuroses, with
an infiltrating growth pattern. As indicated by its name,
aggressive fibromatosis, a desmoid tumor is characterized
by a clinically malignant course, with a reported recur-
rence rate up to 45 % after surgical resection [4].
Treatment of desmoid tumor is a complex condition
with many recognized treatments including active
observation, hormonal therapy, nonsteroidal anti-
inflammatory drugs (NSAIDs), chemotherapy, radio-
therapy, and surgical resection [5]. As desmoid tumors
sometimes exhibit characteristics of stable or regress,
the conservative approach is recommended [6]. In this
case, the tumor grew more than 7 cm in just 3 months
and the patient complained the tumor pain, so it was
necessary to provide the aggressive treatments. Radiother-
apy has been adopted as a primary treatment in patients
who undergo progression during observation. Mounting
literature supports this approach, with several groups
reporting long term local control in 70–93 % of patients
at doses of 50–60 Gy (1.8–2 Gy/fraction) [7, 8]. It is also
reported that the radiotherapy combined with surgical re-
section results in better progression-free survival time
(PFS) than surgery alone [9]. But simultaneously, radio-
therapy has a risk to cause damage to the neighboring
intestine and organ such as perforation or abscess forma-
tion, and potential late radiation effects, including second
malignancies [10]. It was reported a partial response of
hormone therapy (tamoxifen) for desmoid tumor in male
patients, 24~54 months after treatment initiation as well
as female patients [11]. And, there is some evidence that
the treatments are most effective when NSAIDs and
hormonal therapies are given together [12]. Various
chemotherapy regimes were reported and most of them
were used as combination, included methotrexate with
vinblastine or vinorelbine, doxorubicin with dacarbazine,
doxorubicin with cyclophosphamide and vincristine, and
actinomycin-D-based chemotherapy. The average response
rate of them was 50 % (range 17~100 %) [13]. Although
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Fig. 1 Abdominal computed tomography (CT) scan. CT scan revealed the desmoid tumor in abdominal wall (solid white arrow in a and c).
a Pretreatment phase, b Carbon ion treatment plan and c 3 years after ion radiotherapy were shown
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hormonal therapies, nonsteroidal anti-inflammatory drugs
(NSAIDs), interferon, or chemotherapy are options for
unresectable or recurrent disease, the appropriate thera-
peutic approach has not yet been fully elucidated [14].
Carbon ion radiotherapy can precisely irradiate the
target lesion, thereby reducing its adverse effects on the
adjacent intestinal tracts. Photon beam sensitivity varies
with the type of tumor, whereas carbon ion radiotherapy,
which uses carbon (C) molecules, can be expected to
have potent effects on all types of tumor, irrespective of
sensitivity [15]. The finding that carbon ion radiotherapy
was effective for recurrent desmoid tumor of the abdom-
inal wall in this patient will lead to an increase in treat-
ment options and thus have important implications for
patients suffering from this disease and for the physi-
cians treating them. In addition, this is the first report of
a case of desmoid tumor successfully treated with car-
bon ion radiotherapy. We hope that our report will be of
some help in determining the treatment strategy for this
disease.
Conclusions
This report presents a first case that the carbon ion radio-
therapy has been effective for the unresected desmoid
tumor.
Endnotes
1The carbon ion beam dose is reported in Gy (RBE),
which is defined as the physical dose multiplied by the
RBE of the protons or carbon ions. For example, 2 Gy
(RBE) of carbon ion radiotherapy is biologically equiva-
lent to 2 Gy of photon radiotherapy. Biological effects of
carbon ion radiotherapy at HIBMC have been evaluated
in vitro and in vivo, and the RBE values for carbon ion
irradiation were determined to be 2–3.7 (depending on
the depth in the spread-out Bragg peaks) [16].
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